The Role of Vitamin D3 Therapy in Pediatric Bronchiectasis Severity (CF versus Non-CF Patients) ()
Affiliation(s)
1Department of Pediatrics, Pulmonolgy Division, Ain Shams University Children’s Hospital, Faculty of Medicine, Cairo, Egypt.
2Department of Clinical Pathology, Ain Shams University Hospital, Faculty of Medicine, Cairo, Egypt.
3Ministry of Health, Faculty of Medicine, Cairo, Egypt.
ABSTRACT
Objective: To determine and compare the effect of vitamin D3 supplementation on
modifying the disease severity in cystic fibrosis (CF) and non-CF bronchiectasis
pediatric patients. Methods: A randomized clinical trial evaluating the role of oral vitamin D3
supplementation for six months, was performed in forty patients with CF and non-CF bronchiectasis under
the age of 18 years with vitamin D deficiency or insufficiency. The primary
outcome was to reach the sufficient Vitamin D level, the secondary outcome was
to reevaluate bronchiectasis severity by following up the frequency, severity
of pulmonary exacerbations and lung function after vitamin D3 supplementation. Results: Forty patients completed the trial. The percentage of improvement of
vitamin D level after vitamin D3 supplementation for six months was
significantly higher in CF (88.3%) than non-CF bronchiectasis patients (59.82%) (P = 0.03). Additionally, moderate to
severe pulmonary exacerbations significantly decreased by more than 60%, 45% (P = 0.001, 0.005) and frequent exacerbations decreased by 15%,
10% (P = 0.327, 0.490), while the
forced expiratory volume in 1 (FEV1) significantly increased by 17% and 15% in
non CF bronchiectasis and CF patients respectively (p < 0.001). Conclusions: Vitamin D3 therapy was effective in decreasing the frequency
and severity of pulmonary exacerbations and preserving lung function. Thereby,
improving the disease severity even more in non-CF bronchiectasis than CF patients.
Share and Cite:
Ali, H. , Deraz, T. , Mohamed, D. and Mahmoud, M. (2020) The Role of Vitamin D3 Therapy in Pediatric Bronchiectasis Severity (CF versus Non-CF Patients).
Open Journal of Pediatrics,
10, 521-534. doi:
10.4236/ojped.2020.103053.